Study guide
22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
Key Takeaways Explain This Topic AI
High-risk (massive) pulmonary embolism with haemodynamic instability is treated with systemic thrombolysis unless contraindicated, with surgical embolectomy or catheter-directed therapy as alternatives; intermediate-risk patients are anticoagulated and monitored.
Life-threatening asthma features include S p O 2 S_p\text{O}_2 S p O 2 below 92%, a silent chest, exhaustion, arrhythmia, hypotension, and a normal or raised P a CO 2 P_a\text{CO}_2 P a CO 2 , which signals imminent respiratory failure.
Non-invasive ventilation is indicated in acute hypercapnic COPD exacerbations with pH 7.25-7.35 (and can be trialled below 7.25 with close supervision) and reduces intubation and mortality.
High-flow nasal oxygen delivers heated, humidified gas at up to about 60 L/min with a precise F I O 2 F_I\text{O}_2 F I O 2 , generates a small PEEP effect and washes out nasopharyngeal dead space.
Cardiogenic shock is defined by hypotension with signs of hypoperfusion despite adequate filling; treatment includes revascularisation for acute myocardial infarction, inotropes or vasopressors, and mechanical circulatory support in selected patients.
Last updated: October 2026
22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
- Pulmonary Embolism (PE)
- Clinical Probability and Diagnosis
Symptoms include dyspnoea, pleuritic pain, haemoptysis, syncope and tachycardia. Clinical probability is assessed with the Wells or revised Geneva scores. In low or intermediate probability, a normal D-dimer (age-adjusted after 50 years) excludes PE; otherwise CT pulmonary angiography is the main test. Bedside echocardiography showing right ventricular dysfunction supports the diagnosis in an unstable patient who cannot be moved.
Risk Stratification (ESC 2019)
Risk Features Management
High Cardiac arrest, obstructive shock or persistent hypotension (systolic below 90 mmHg) Systemic thrombolysis (for example alteplase 100 mg over 2 hours, or faster in arrest); surgical embolectomy or catheter-directed therapy if thrombolysis is contraindicated or fails
Intermediate-high Stable, but right ventricular dysfunction on imaging and raised troponin Anticoagulation with close monitoring; rescue thrombolysis if haemodynamic decompensation occurs
Intermediate-low Stable, with one or neither of these markers (or PESI class III-V) Anticoagulation
Low Stable, low PESI or sPESI score, no right ventricular dysfunction Anticoagulation, possible early discharge
Anticoagulation: low molecular weight heparin or a DOAC in most patients; unfractionated heparin when thrombolysis or intervention may be needed or in severe renal impairment.
Supportive care in shock: avoid large fluid boluses, which can worsen right ventricular dilation; use noradrenaline; avoid intubation where possible because induction and positive pressure can precipitate cardiovascular collapse. ECMO may be considered in refractory cases.
- Acute Severe Asthma
- Severity Assessment (Adults)
- Category Features
- Moderate Increasing symptoms; peak expiratory flow (PEF) above 50-75% best or predicted
Acute severe Any of: PEF 33-50%, respiratory rate 25/min or more, heart rate 110/min or more, inability to complete sentences
Life-threatening Any of: PEF below 33%, S p O 2 S_p\text{O}_2 S p O 2 below 92%, P a O 2 P_a\text{O}_2 P a O 2 below 8 kPa, normal P a CO 2 P_a\text{CO}_2 P a CO 2 (4.6-6.0 kPa) , silent chest, cyanosis, poor respiratory effort, arrhythmia, exhaustion, altered consciousness, hypotension
Near-fatal Raised P a CO 2 P_a\text{CO}_2 P a CO 2 or need for mechanical ventilation with raised inflation pressures
Treatment
Oxygen to S p O 2 S_p\text{O}_2 S p O 2 of 94-98%.
Nebulised salbutamol 5 mg (back-to-back or continuous if severe) and ipratropium 0.5 mg every 4-6 hours.
Corticosteroids: prednisolone 40-50 mg orally or hydrocortisone 100 mg intravenously.
Magnesium sulphate 1.2-2 g intravenously over 20 minutes for severe or life-threatening asthma.
Intravenous aminophylline or salbutamol only on senior advice.
Intubation and ventilation for exhaustion, deteriorating consciousness or respiratory arrest. Use ketamine or propofol for induction; ventilate with a low rate, small tidal volume and long expiratory time , accepting permissive hypercapnia, to avoid dynamic hyperinflation . If hypotension occurs after intubation, disconnect the ventilator briefly to allow gas trapping to empty and exclude tension pneumothorax.
Acute Exacerbation of COPD
Controlled oxygen: target S p O 2 S_p\text{O}_2 S p O 2 88-92% in patients at risk of hypercapnic respiratory failure (Venturi masks).
Nebulised bronchodilators, oral prednisolone 30-40 mg for 5 days, and antibiotics when sputum is purulent or there are signs of pneumonia.
Non-invasive ventilation for persistent hypercapnic acidosis despite optimal treatment (see below).
- Non-Invasive Respiratory Support
- Non-Invasive Ventilation (NIV)
Bilevel positive airway pressure (inspiratory positive airway pressure, IPAP, and expiratory positive airway pressure, EPAP) via a face or nasal mask.
Strongest indications:
Acute hypercapnic respiratory failure in COPD with pH 7.25-7.35 and P a CO 2 P_a\text{CO}_2 P a CO 2 above 6.5 kPa despite medical therapy (reduces intubation and mortality); patients with pH below 7.25 can be trialled in a critical care setting with a low threshold for intubation.
Cardiogenic pulmonary oedema (CPAP or NIV improves oxygenation and work of breathing).
Obesity hypoventilation and neuromuscular or chest wall disease.
Immunocompromised patients with hypoxaemic failure (selected).
Typical settings: start IPAP about 15 cmH2O and EPAP about 4-5 cmH2O, increasing IPAP towards 20-25 cmH2O as tolerated; reassess blood gases at 1-2 hours.
Contraindications: respiratory arrest, inability to protect the airway, severe agitation or reduced consciousness (except hypercapnic encephalopathy in COPD), facial trauma, recent upper gastrointestinal surgery, vomiting, untreated pneumothorax and haemodynamic instability. Failure to improve within 1-4 hours should prompt escalation to intubation if appropriate.
Continuous Positive Airway Pressure (CPAP)
Provides a constant pressure, recruits alveoli, increases FRC and reduces left ventricular afterload; used for cardiogenic pulmonary oedema, obstructive sleep apnoea and hypoxaemic respiratory failure.
High-Flow Nasal Oxygen (HFNO)
Heated, humidified gas at up to about 60 L/min with a controlled F I O 2 F_I\text{O}_2 F I O 2 (21-100%).
Effects: matches or exceeds patient inspiratory flow so the delivered F I O 2 F_I\text{O}_2 F I O 2 is reliable, washes out nasopharyngeal dead space, produces a small flow-dependent PEEP (about 1 cmH2O per 10 L/min with the mouth closed), and improves comfort and secretion clearance.
Used for hypoxaemic respiratory failure (the FLORALI trial suggested benefit in severe hypoxaemia), post-extubation support and preoxygenation and apnoeic oxygenation.
The ROX index ( S p O 2 / F I O 2 S_p\text{O}_2/F_I\text{O}_2 S p O 2 / F I O 2 divided by respiratory rate) helps predict HFNO failure; a value below about 3.85 at 12 hours suggests a high risk of intubation.
- Acute Heart Failure and Cardiogenic Shock
- Assessment
Classify the patient by congestion ("wet" or "dry") and perfusion ("warm" or "cold"). Investigate with ECG, troponin, natriuretic peptides, echocardiography, chest radiograph and lactate, and look for precipitants ( CHAMPIT : acute Coronary syndrome, Hypertensive emergency, Arrhythmia, Mechanical cause, Pulmonary embolism, Infection, Tamponade).
Treatment of Acute Pulmonary Oedema
Sit the patient up, give oxygen to S p O 2 S_p\text{O}_2 S p O 2 above 90%, and use CPAP or NIV for respiratory distress.
Intravenous loop diuretics for congestion.
Vasodilators (nitrates) when systolic blood pressure is adequate (above about 110 mmHg), especially in hypertensive pulmonary oedema.
Routine opioids are not recommended.
Cardiogenic Shock
Definition: systolic blood pressure below 90 mmHg (or vasopressors needed) with signs of hypoperfusion (cold peripheries, oliguria, confusion, raised lactate) despite adequate filling.
Acute myocardial infarction is the commonest cause: emergency revascularisation of the culprit lesion improves survival.
Noradrenaline is the preferred vasopressor; dobutamine or levosimendan as inotropes; milrinone is an inodilator.
Mechanical circulatory support (intra-aortic balloon pump, microaxial flow pumps, venoarterial ECMO) in selected patients; routine intra-aortic balloon pumping did not improve survival in IABP-SHOCK II, and venoarterial ECMO did not reduce mortality in ECLS-SHOCK.
Treat mechanical complications (acute mitral regurgitation, ventricular septal rupture, tamponade) surgically.
Right Ventricular Failure
Common in PE, pulmonary hypertension and inferior myocardial infarction. Principles: optimise preload (avoid overload), maintain systemic pressure to perfuse the right coronary artery (noradrenaline, vasopressin), reduce pulmonary vascular resistance (avoid hypoxaemia, hypercapnia and acidosis; consider inhaled nitric oxide), and support contractility (dobutamine, milrinone, levosimendan).